Surrozen, Inc. (SRZNW) 股票分析

公司概述

Surrozen, Inc. (SRZNW) is a biotechnology enterprise dedicated to the discovery and development of drug candidates designed to selectively modulate the Wnt pathway for the purpose of tissue repair. The company focuses on antibody-based therapeutics targeting specific disease areas such as conditions affecting the intestine, liver, retina, cornea, and lung. Although the company operates within the biotechnology sector, specific industry classification data is not available in the current reporting period. The firm employs a workforce of 44 individuals and reports a trailing twelve-month revenue of $3.48 million. The absence of reported market capitalization and price-to-sales metrics suggests that the firm's valuation is currently driven by asset backing rather than earnings multiples, positioning it as a capital-intensive pre-revenue or early-stage development entity where traditional profitability measures are not yet applicable to its operational scale.

财务健康

Surrozen, Inc. reported a trailing twelve-month revenue of $3.48 million, yet simultaneously recorded a net income loss of $242,026,000 and an EBITDA of $-41,555,000. The substantial gap between the modest revenue of $3.48 million and the massive net loss of $242,026,000 reveals an extreme cost structure where expenses significantly outweigh all generated sales, indicating heavy research and development burn rates typical of late-stage biotechnology ventures. The company's free cash flow stands at $-16,856,500, which indicates a continuous consumption of cash reserves required to sustain operations and advance clinical programs without generating positive cash flow from core activities. All three margin metrics reflect this financial reality: the gross margin is 0.0%, the operating margin is -2393.8%, and the profit margin is 0.0%. These figures collectively indicate that the company is not currently profitable at the operational or bottom-line level, with the negative operating margin suggesting that operating expenses are many times larger than the revenue base. The balance sheet, however, maintains a cash position of $89.25M against total debt of $6.64M, providing a significant liquidity buffer despite the lack of a reported debt-to-equity ratio. The current ratio is listed at 9.22, which indicates a highly conservative short-term liquidity position where current assets are more than nine times greater than current liabilities. Return on assets is reported at -35.7%, while return on equity is N/A, revealing that management effectiveness in generating returns is currently negative due to the accumulated losses relative to the company's asset base and equity structure.

估值评估

Valuation multiples for Surrozen, Inc. are not available in the standard sense, as the trailing P/E ratio, forward P/E, and EV/EBITDA are all N/A. The absence of these ratios implies that the market cannot value the company based on earnings power or enterprise value multiples due to the negative earnings profile and lack of profitability. Consequently, the price-to-book ratio is reported as -0.00, which indicates that the market capitalization relative to shareholders' equity is not a meaningful metric in the traditional sense, likely due to the company's negative net asset position or the way equity is calculated against significant accumulated deficits. Similarly, the price-to-sales ratio and EV/EBITDA are N/A, suggesting that investors cannot rely on revenue multiples or enterprise value measures to gauge intrinsic value at this stage of development. The stock's price action is constrained, with a 52-week high of $0.02 and a 52-week low of $0.02, meaning the current trading price sits at 0% deviation from the 52-week high and low. The beta value is 0.52, which indicates that the stock's price volatility is approximately half that of the broader market, suggesting lower sensitivity to general market movements compared to larger-cap equities.

Growth & Income

The company's financial trajectory shows a year-over-year revenue growth rate of -19.4%, while the earnings growth rate is N/A due to the persistent net losses. The decline in revenue indicates a contraction in sales or a reduction in recurring business, and without positive earnings, there is no earnings growth to compare against revenue dynamics. As the company does not pay dividends, the dividend yield and payout ratio are both N/A, meaning there is no distribution of cash to shareholders. Instead, the firm retains all available cash flow to fund ongoing research and development efforts rather than distributing income to investors. The overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, reflecting the capital-intensive nature of the biotechnology sector where growth is currently being funded through cash reserves rather than organic earnings expansion or shareholder returns.